REG-Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
Lakefront Biotherapeutics completed the sale of its early-stage preclinical CAR-T cell therapy pipeline to Belgium-based Armed Cell Therapeutics. Deal terms include an €8 million upfront payment, up to $230 million in milestone payments, and a low-single-digit royalty to Lakefront; the assets originated from AboundBio, acquired in 2022.
Key figures
- Deal Value Usd
- €8 million upfront plus up to $230 million in milestone payments
- Royalty
- low-single-digit royalty
- Upfront payment eur
- 8000000
- Milestone payments usd
- 230000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.